Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 26, Issue 4, 2011, Pages 627-645

  Bloudek, Lisa M ^a   Spackman, D Eldon ^b   Blankenburg, Michael ^c   Sullivan, Sean D ^d  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; amyloid protein; biomarkers; diagnosis; emission computed; magnetic resonance imaging; sensitivity and specificity; single photon; tau proteins; tomography

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HUMAN; MEDICAL LITERATURE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW;

EID: 80055039147     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110458     Document Type: Article

References (146)

1. Jobst KA, Barnetson LP, Shepstone BJ (1998) Accurate prediction of histologically confirmed Alzheimers disease and the differential diagnosis of dementia: the use of NINCDSADRDA and DSM-III-R criteria, spect, X-ray CT, and apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 10, 271-302. (Pubitemid 28470188)
2. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimers disease. N Engl J Med 338, 506-511. (Pubitemid 28103134)
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, OBrien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
4. Carrillo MC, Blackwell A, Hampel H, Lindborg J, Sperling R, Schenk D, Sevigny JJ, Ferris S, Bennett DA, Craft S, Hsu T, Klunk W (2009) Early risk assessment for Alzheimers disease. Alzheimers Dement 5, 182-196.
5. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B (2007) Recommendations for the diagnosis and management of Alzheimers disease and other disorders associated with dementia. EFNS guideline. Eur J Neurol 14, e1-e26. (Pubitemid 46088015)
6. Braak H, Braak E (1995) Staging of Alzheimers diseaserelated neurofibrillary changes. Neurobiol Aging 16, 271-278.
7. Yuan Y, Gu ZX, Wei WS (2009) Fluorodeoxyglucosepositron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 30, 404-410.
8. Small GW (2006) Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 19, 180-185. (Pubitemid 44154858)
9. Mazziotta JC, Frackowiak RS, Phelps ME (1992) The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 22, 233-246.
10. Bradley KM, OSullivan VT, Soper ND, Nagy Z, King EM, Smith AD, Shepstone BJ (2002) Cerebral perfusion SPECT correlated with Braak pathological stage in Alzheimers disease. Brain 125, 1772-1781.
11. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Pre-clinical detection of Alzheimers disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20, 843-854.
12. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT (2004) Alzheimer disease: operating characteristics of PET-a meta-analysis. Radiology 231, 73-80. (Pubitemid 38375412)
13. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimers disease -a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80, 966-975.
14. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimers disease. Mol Neurobiol 24, 87-97. (Pubitemid 34066679)
15. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Dis 6, 295-303. (Pubitemid 46505880)
16. Mistur R, Mosconi L, Santi SD, Guzman M, LiY, TsuiW, de Leon MJ (2009) Current challenges for the early detection of Alzheimers disease: brain imaging and CSF studies. J Clin Neurol 5, 153-166.
17. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF (1994) Reliability and validity of NINCDSADRDA criteria for Alzheimers disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 51, 1198-1204.
18. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE (2000) FDG-PET imaging in pathologically verified dementia. J Nucl Med 41, 1920-1928.
19. Holmes C, Cairns N, Lantos P, Mann A (1999) Validity of current clinical criteria for Alzheimers disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 174, 45-50. (Pubitemid 29037883)
20. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB (1999) Clinico- neuropathological correlation of Alzheimers disease in a community-based case series. J Am Geriatr Soc 47, 564-569. (Pubitemid 29215585)
21. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877. (Pubitemid 47329586)
22. McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, Snowden JS, Varma AR (2007) Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimers disease. J Neurol Neurosurg Psychiatry 78, 350-335.
23. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ (2009) Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimers disease. J Alzheimers Dis 16, 351-362.
24. Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, Niinistö L, Rastas S, Oinas M, Scheltens P, Erkinjuntti T (2007) The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 69, 1521-1527. (Pubitemid 47537859)
25. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, Kalaria RN, OBrien JT (2009) Medial temporal lobe atrophy on MRI differentiates Alzheimers disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132, 195-203.
26. Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C (2009) Markers of Alzheimers disease in a population attending a memory clinic. Alzheimers Dement 5, 307-317.
27. McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr Holland D, Karow DS, Pung CJ, Brewer JB, Dale AM (2009) Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251, 195-205.
28. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr (2009) Alzheimers Disease Neuroimaging Initiative MRI and CSF biomarkers in normal, MCI, andADsubjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
29. Colliot O, Chételat G, Chupin M, Desgranges B, Magnin B, Benali H, Dubois B, Garnero L, Eustache F, Lehéricy S (2008) Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology 248, 194-201.
30. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, Barker W, Schofield E, Wu Y, Potter H (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986-1992.
31. Matsunari I, Samuraki M, Chen WP, Yanase D, Takeda N, Ono K, Yoshita M, Matsuda H, Yamada M, Kinuya S (2007) Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimers disease: aging effect on diagnostic performance. J Nucl Med 48, 1961-1970. (Pubitemid 350232304)
32. Hanyu H, Shimizu S, Tanaka Y, Kanetaka H, Iwamoto T, Abe K (2005) Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimers disease. Neurosci Lett 380, 166-169. (Pubitemid 40602349)
33. Wang H, Shu L, Xie J, Zhang H, Zhang D (2004) Diagnostic utility of neuropsychological performance and quantitative MRI-based measurement in Alzheimer disease. Alzheimer Dis Assoc Disord 18, 163-170. (Pubitemid 39202192)
34. Bottino CM, Castro CC, Gomes RL, Buchpiguel CA, Marchetti RL, Neto MR (2002) Volumetric MRI measurements can differentiate Alzheimers disease, mild cognitive impairment, and normal aging. Int Psychogeriatr 14, 59-72. (Pubitemid 34625564)
35. Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, Bordiga G, DeCarli C, Laakso MP, Soininen H, Testa C, Zanetti O, Trabucchi M (2002) Radial width of the temporal horn: a sensitive measure in Alzheimer disease. Am J Neuroradiol 23, 35-47. (Pubitemid 34098259)
36. Varma AR, Adams W, Lloyd JJ, Carson KJ, Snowden JS, Testa HJ, Jackson A, Neary D (2002) Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimers disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 105, 261-269. (Pubitemid 34407228)
37. Hanyu H, Asano T, Sakurai H, Takasaki M, Shindo H, Abe K (2001) Magnetization transfer measurements of the hippocampus in the early diagnosis of Alzheimers disease. J Neurol Sci18, 879-884.
38. OBrien JT, Ames D, Desmond P, Lichtenstein M, Binns D, Schweitzer I, Davis S, Tress B (2001) Combined magnetic resonance imaging and single-photon emission tomography scanning in the discrimination of Alzheimers disease from age-matched controls. Int Psychogeriatr 13, 149-161. (Pubitemid 32703328)
39. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS (2000) Use of structural magnetic resonance imaging to predict who will get Alzheimers disease. Ann Neurol 47, 430-439. (Pubitemid 30194598)
40. Golebiowski M, Barcikowska M, Pfeffer A (1999) Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type. Dement Geriatr Cogn Disord 10, 284-288. (Pubitemid 29281019)
41. Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hänninen T, Helkala EL, Vainio P, Riekkinen PJ Sr (1998) MRI of the hippocampus in Alzheimers disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 19, 23-31. (Pubitemid 28167791)
42. Pucci E, Belardinelli N, Regnicolo L, Nolfe G, Signorino M, Salvolini U, Angeleri F (1998) Hippocampus and parahip pocampal gyrus linear measurements based on magnetic resonance in Alzheimers disease. Eur Neurol 39, 16-25. (Pubitemid 28024927)
43. OBrien JT, Desmond P, Ames D, Schweitzer I, Chiu E, Tress B (1997) Temporal lobe magnetic resonance imaging can differentiate Alzheimers disease from normal aging, depression, vascular dementia and other causes of cognitive impairment. Psychol Med 27, 1267-1275. (Pubitemid 27494092)
44. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C (1997) The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photonemission-computed-tomography for the diagnosis of Alzheimer disease in a community dwelling elderly population. Alzheimer Dis Assoc Disord 11, 63-70. (Pubitemid 27271975)
45. Frisoni GB, Beltramello A, Weiss C, Geroldi C, Bianchetti A, Trabucchi M (1996) Linear measures of atrophy in mild Alzheimers disease. AJNR Am J Neuroradiol 17, 913-923. (Pubitemid 26149094)
46. Desmond PM, OBrien JT, Tress BM, Ames DJ, Clement JG, Clement P, Schweitzer I, Tuckwell V, Robinson GS (1994) Volumetric and visual assessment of the mesial temporal structures in Alzheimers disease. Aust NZ J Med 24, 547-553.
47. Erkinjuntti T, Lee DH, Gao F, Steenhuis R, Eliasziw M, Fry R, Merskey H, Hachinski VC (1993) Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimers disease. Arch Neurol 50, 305-310. (Pubitemid 23069618)
48. Scheltens P, Barkhof F, Valk J, Algra PR, van der Hoop RG, Nauta J, Wolters EC (1992) White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimers disease. Evidence for heterogeneity. Brain 115, 735-748.
49. Rossi R, Joachim C, Smith AD, Frisoni GB (2004) The CT-based radial width of the temporal horn: pathological validation inADwithout cerebrovascular disease. Int J Geriatr Psychiatry 19, 570-574. (Pubitemid 38878008)
50. Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, Bordiga G, DeCarli C, Laakso MP, Soininen H, Testa C, Zanetti O, TrabucchiM(2002) Radial width of the temporal horn: a sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol 23, 35-47. (Pubitemid 34098259)
51. Denihan A, Wilson G, Cunningham C, Coakley D, Lawlor BA (2000) CT measurement of medial temporal lobe atrophy in Alzheimers disease, vascular dementia, depression and paraphrenia. Int J Geriatr Psychiatry 15, 306-312. (Pubitemid 30315745)
52. OBrien JT, Metcalfe S, Swann A, Hobson J, Jobst K, Ballard C, McKeith I, Gholkar A (2000) Medial temporal lobe width on CT scanning in Alzheimers disease: comparison with vascular dementia, depression and dementia with Lewy bodies. Dement Geriatr Cogn Disord 11, 114-118. (Pubitemid 30114093)
53. Pasquier F, Hamon M, Lebert F, Jacob B, Pruvo JP, Petit H (1997) Medial temporal lobe atrophy in memory disorders. J Neurol 244, 175-181. (Pubitemid 27099855)
54. Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C (2009) Markers of Alzheimers disease in a population attending a memory clinic. Alzheimers Dement 5, 307-317.
55. Haense C, Herholz K, Jagust WJ, Heiss WD (2009) Performance of FDG PET for detection of Alzheimers disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord 28, 259-266.
56. Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, Drzezga A, Stern Y (2008) Multivariate and univariate neuroimaging biomarkers of Alzheimers disease. Neuroimage 40, 1503-1515.
57. McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF (2008) Positron emission tomography facilitates diagnosis of early-onset Alzheimers disease. Eur Neurol 59, 31-37. (Pubitemid 350277257)
58. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimers disease, and other dementias. J Nucl Med 49, 390-398. (Pubitemid 351355204)
59. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimers disease. Brain 130, 2616-2635. (Pubitemid 47511706)
60. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877. (Pubitemid 47329586)
61. Matsunari I, Samuraki M, Chen WP, Yanase D, Takeda N, Ono K, Yoshita M, Matsuda H, Yamada M, Kinuya S (2007) Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimers disease: aging effect on diagnostic performance. J Nucl Med 48, 1961-1970. (Pubitemid 350232304)
62. Nihashi T, Yatsuya H, Hayasaka K, Kato R, Kawatsu S, Arahata Y, Iwai K, Takeda A, Washimi Y, Yoshimura K, Mizuno K, Kato T, Naganawa S, Ito K (2007) Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimers disease using 3D-SSP analysis in the same patients. Radiat Med 25, 255-262. (Pubitemid 351928035)
63. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D (2005) Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62, 1728-1733. (Pubitemid 41626670)
64. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46, 1625-1632. (Pubitemid 46211586)
65. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, MielkeR, Kalbe E, Zündorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenterFDGPET. Neuroimage 17, 302-316.
66. Arnáiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A (2001) Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12, 851-855. (Pubitemid 32222729)
67. Silverman DHS, Small GW, Chang CY, Cummings JL, Kowell AP, Czernin J, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120-2127. (Pubitemid 34041597)
68. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, Itoh M, Shin RW, Trojanowski JQ, Sasaki H (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 162, 247-256. (Pubitemid 30217720)
69. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE (2000) FDG-PET imaging in pathologically verified dementia. J Nucl Med 41, 1920-1928.
70. Ohyama M, Senda M, Mishina M, Kitamura S, Tanizaki N, Ishii K, Katayama Y (2000) Semi-automatic ROI placement system for analysis of brain PET images based on elastic model: application to diagnosis of Alzheimers disease.Keio J Med 49(1), A105-A106. (Pubitemid 30210258)
71. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Hashimoto M, Hirono N, Shimomura T, Mori E (1998) Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimers disease. Neurology 51, 125-130. (Pubitemid 28345371)
72. Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE (1996) Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 198, 837-843. (Pubitemid 26066307)
73. Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, Grassi F, Del Sole A, Franceschi M, Gilardi MC (1994) High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimers disease: comparison with fluorine-18-FDG PET. J Nucl Med 35, 210-216. (Pubitemid 24048307)
74. Szelies B, Mielke R, Herholz K, Heiss WD (1994) Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr Clin Neurophysiol 91, 131-139. (Pubitemid 24246467)
75. Azari NP, Pettigrew KD, Schapiro MB, Haxby JV, Grady CL, Pietrini P, Salerno JA, Heston LL, Rapoport SI, Horwitz B(1993) Early detection of Alzheimers disease: a statistical approach using positron emission tomographic data. J Cereb Blood Flow Metab 13, 438-447. (Pubitemid 23129397)
76. Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D(1993) Comparability of FDG PET studies in probable Alzheimers disease. J Nucl Med 34, 1460-1466. (Pubitemid 23254340)
77. Kippenhan JS, Barker WW, Pascal S, Nagel J, Duara R (1992) Evaluation of a neural-network classifier for PET scans of normal and Alzheimers disease subjects. J Nucl Med 33, 1459-1467.
78. Powers WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, Siegel BA, Morris JC, Berg L (1992) Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimers disease. Neurology 42, 765-770.
79. Grady CL, Haxby JV, Schapiro MB, Gonzalez-Aviles A, Kumar A, Ball MJ, Heston L, Rapoport SI (1990) Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J Neuropsychiatry Clin Neurosci 2, 373-384. (Pubitemid 20371669)
80. Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss W-D(1990) Criteria for the diagnosis of Alzheimers disease with positron emission tomography. Dementia 1, 156.
81. McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, Snowden JS, Varma AR (2007) Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimers disease. J Neurol Neurosurg Psychiatry 78, 350-335.
82. Nihashi T, Yatsuya H, Hayasaka K, Kato R, Kawatsu S, ArahataY, Iwai K, Takeda A, Washimi Y, Yoshimura K, Mizuno K, Kato T, Naganawa S, Ito K (2007) Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimers disease using 3D-SSP analysis in the same patients. Radiat Med 25, 255-262. (Pubitemid 351928035)
83. Bonte FJ, Harris TS, Hynan LS, Bigio EH, White CL, 3rd (2006) Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation. Clin Nucl Med 31, 376-378. (Pubitemid 44315514)
84. Bonte FJ, Harris TS, Roney CA, Hynan LS (2004) Differential diagnosis between Alzheimers and frontotemporal disease by the posterior cingulate sign. J Nucl Med 45, 771-774. (Pubitemid 47618555)
85. Varma AR, Adams W, Lloyd JJ, Carson KJ, Snowden JS, Testa HJ, Jackson A, Neary D (2002) Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimers disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 105, 261-269. (Pubitemid 34407228)
86. Defebvre LJ, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, Steinling M, DestéeA(1999) Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimers disease and idiopathic Parkinsons disease. J Nucl Med 40, 956-962. (Pubitemid 29269214)
87. Bonte FJ, Weiner MF, Bigio EH, White CL, 3rd (1997) Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202, 793-797. (Pubitemid 27093456)
88. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C (1997) The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photonemission-computed-tomography for the diagnosis of Alzheimer disease in a community dwelling elderly population. Alzheimer Dis Assoc Disord 11, 63-70. (Pubitemid 27271975)
89. Greene JD, Miles K, Hodges JR (1996) Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. J Neurol 243, 175-190. (Pubitemid 26026656)
90. van Dyck CH, Lin CH, Smith EO, Wisniewski G, Cellar J, Robinson R, Narayan M, Bennett A, Delaney RC, Bronen RA, Hoffer PB (1996) Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimers disease. J Nucl Med 37, 1749-1755. (Pubitemid 26378354)
91. Van Gool WA, Walstra GJ, Teunisse S, Van der Zant FM, Weinstein HC, Van Royen EA (1995) Diagnosing Alzheimers disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 242, 401-405.
92. Claus JJ, van Harskamp F, Breteler MM, Krenning EP, de Koning I, van der Cammen TJ, Hofman A, Hasan D (1994) The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimers disease: a population-based study. Neurology 44(3 Pt 1), 454-461. (Pubitemid 24098144)
93. McMurdo ME, Grant DJ, Kennedy NS, Gilchrist J, Findlay D, McLennan JM (1994) The value of HMPAO SPECT scanning in the diagnosis of early Alzheimers disease in patients attending a memory clinic. Nucl Med Commun 15, 405-409. (Pubitemid 24184061)
94. Bonte FJ, Tintner R, Weiner MF, Bigio EH, White CL, 3rd (1993) Brain blood flow in the dementias: SPECT with histopathologic correlation. Radiology 186, 361-365. (Pubitemid 23033856)
95. Hanyu H, Abe S, Arai H, Asano T, Iwamoto T, Takasaki M (1993) Diagnostic accuracy of single photon emission computed tomography in Alzheimers disease. Gerontology 39, 260-266. (Pubitemid 23346594)
96. Johnson KA, Kijewski MF, Becker JA, Garada B, Satlin A, Holman BL (1993) Quantitative brain SPECT in Alzheimers disease and normal aging. J Nucl Med 34, 2044-2048. (Pubitemid 23331282)
97. Johnson KA, Holman BL, Rosen TJ, Nagel JS, English RJ, Growdon JH (1990) Iofetamine I 123 single photon emis sion computed tomography is accurate in the diagnosis of Alzheimers disease. Arch Intern Med 150, 752-756. (Pubitemid 20122049)
98. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
99. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S (2009) Improved discrimination of autopsy-confirmed Alzheimers disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 55, 214-218.
100. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
101. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimers disease. Biomarkers 14, 493-501.
102. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimers Disease Neuroimaging Initiative Subjects. Ann Neurol 65, 403-413.
103. Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, Ltaief A, Bennamou S, Limem K (2009) Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol 62, 349-355.
104. Brandt C, Bahl JC, Heegaard NH, Waldemar G, Johannsen P (2008) Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic. Dement Geriatr Cogn Disord 25, 553-558. (Pubitemid 351957419)
105. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 29, 812-818. (Pubitemid 351601894)
106. Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G (2006) Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27, 1202-1211. (Pubitemid 44067302)
107. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, Du Y, Möller HJ, Bergmann A, Hampel H (2005) Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimers disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 57, 813-816.
108. Herukka SK, Hallikainen M, Soininen H, Pirttila T (2005) CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297.
109. Ivanoiu A, Sindic CJ (2005) Cerebrospinal fluidTAUprotein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimers disease and correlation with the neuropsychological examination. Neurocase 11, 32-39. (Pubitemid 40372858)
110. Kapaki E, Liappas I, ParaskevasGP, Theotoka I, RabavilasA (2005) The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimers disease in the early stages. Int J Geriatr Psychiatry 20, 722-729. (Pubitemid 41158716)
111. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, Urbani A, Giordano A, Martorana A, Orlacchio A, Federici G, Bernardi G (2005) AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237, 83-88. (Pubitemid 41384018)
112. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K (2004) Core Value of CSF betaamyloid1-and tau as predictors of Alzheimers disease in patients with mild cognitive impairment. Mol Psychiatry 9, 705-710. (Pubitemid 38932175)
113. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P (2004) Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584. (Pubitemid 38608199)
114. Kapaki E, Paraskevas GP, Zalonis I, Zournas C (2003) CSF tau protein and beta-amyloid(1-42) in Alzheimers disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 10, 119-128. (Pubitemid 36308205)
115. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide(42). Arch Neurol 60, 1202-1206. (Pubitemid 37099624)
116. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1 42) and tau levels in CSF. Neurology 52, 1555-1562. (Pubitemid 29220627)
117. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ (2009) Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimers disease. J Alzheimers Dis 16, 351-362.
118. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30, 682-690.
119. Boban M, Grbíc K, Mladinov M, Hof PR, Süssmair C, Ackl N, Staníc G, Bader B, Danek A, Simíc G (2008) Cerebrospinal fluid markers in differential diagnosis of Alzheimers disease and vascular dementia. Coll Antropol 32, 31-36.
120. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159. (Pubitemid 351822410)
121. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr., Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696-1702. (Pubitemid 37521622)
122. Schönknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hampel H, Schröder J (2003) Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimers disease. Neurosci Lett 339, 172-174. (Pubitemid 36254803)
123. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59, 1267-1272. (Pubitemid 34856379)
124. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granérus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimers disease. J Neurol Neurosurg Psychiatry 70, 624-630. (Pubitemid 32397998)
125. Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M, Ikeda M, Tomidokoro Y, Shizuka M, Watanabe M, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Nishimura T, NakamuraY, Takeda M, Urakami K, Adachi Y, Nakashima K, Arai H, Sasaki H, Kanemaru K, Yamanouchi H, Yoshida Y, Ichise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Yoshida H, Toji H, Nakamura S, Hirai S (2002) Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging 23, 363-370. (Pubitemid 34312018)
126. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GMJr (2000) Combined assessment of tau and neuronal thread protein in Alzheimers disease CSF. Neurology 54, 1498-1504. (Pubitemid 30210474)
127. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimers disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 22, 77-78. (Pubitemid 33622091)
128. Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Müller U, Guder W (1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord 12, 372-377. (Pubitemid 29050754)
129. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (1999) Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53, 1488-1494. (Pubitemid 29491942)
130. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF tau, Abeta 1-40 andAbeta 1-42(43) as a biochemical marker of Alzheimers disease. J Neurol Sci 158, 134-140. (Pubitemid 28342076)
131. Arai H, Higuchi S, Saskai H (1997) Genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimers disease. Gerontology 43, 2-10. (Pubitemid 27230642)
132. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimers disease. Ann Neurol 50, 150-156. (Pubitemid 32738138)
133. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimers disease. Biomarkers 14, 493-501.
134. Ravaglia S, Bini P, Sinforiani E, Franciotta D, Zardini E, Tosca P, Moglia A, Costa A (2008) Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimers disease and vascular dementia. Neurol Sci 29, 417-423.
135. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260, 33-37. (Pubitemid 47212190)
136. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bläser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E (2006) Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimers disease and dementia with Lewy bodies. Clin Chem Lab Med 44, 1472-1480. (Pubitemid 44967698)
137. Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A, Tapiola T, Rapoport SI, Pirttilä T, Möller HJ, Hampel H (2003) Differentiation of geriatric major depression from Alzheimers disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 160, 376-379. (Pubitemid 41110469)
138. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schröder J, Zinkowski RP, Bouwman FH, Schönknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H (2007) Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69, 2205-2212. (Pubitemid 350294675)
139. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59, 1729-1734. (Pubitemid 35340483)
140. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased betaamyloid1-and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103. (Pubitemid 37430211)
141. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
142. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153.
143. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, OKeefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Ping Kung M, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, VillemagneVL(2008) Imaging of amyloid in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7, 129-135.
144. Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BN (2010) Molecular imaging in the diagnosis of Alzheimers disease: visual assessment of 11C]PIB and 18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 81, 882-884.
145. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, OKeefe G, Masters CL, Rowe CC (2007) Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimers disease. J Nucl Med 48, 547-552. (Pubitemid 47571408)
146. Devanand DP, Mikhno A, Pelton GH, Cuasay K, Pradhaban G, Dileep Kumar JS, Upton N, Lai R, Gunn RN, Libri V, Liu X, van Heertum R, Mann JJ, Parsey RV (2010) Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG)PETin patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 23, 185-198.